$79.16
0.08% yesterday
NYSE, Jun 30, 10:10 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$79.16
+2.32 3.02% 1M
-19.21 19.53% 6M
-20.32 20.43% YTD
-48.74 38.11% 1Y
-12.01 13.17% 3Y
+5.42 7.36% 5Y
+24.88 45.83% 10Y
+49.79 169.54% 20Y
NYSE, Closing price Mon, Jun 30 2025
+0.06 0.08%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Basic
Market capitalization
$198.6b
Enterprise Value
$224.2b
Net debt
$25.6b
Cash
$9.2b
Shares outstanding
2.5b
Valuation (TTM | estimate)
P/E
11.50 | 8.80
P/S
3.11 | 3.02
EV/Sales
3.51 | 3.41
EV/FCF
13.16
P/B
4.12
Dividends
DPS
$3.12
Yield 1Y | 5Y
3.94% | 2.95%
Growth 1Y | 5Y
5.41% | 7.68%
Payout 1Y | 3Y
46.29% | 70.53%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$63.9b | $65.7b
EBITDA
$26.2b | $30.4b
EBIT
$21.6b
Net Income
$17.4b | $22.6b
Free Cash Flow
$17.0b
Growth (TTM | estimate)
Revenue
4.10% | 2.42%
EBITDA
-0.39% | 8.94%
EBIT
-3.79%
Net Income
656.03% | 32.19%
Free Cash Flow
54.34%
Margin (TTM | estimate)
Gross
78.17%
EBITDA
41.06% | 46.24%
EBIT
33.84%
Net
27.27% | 34.43%
Free Cash Flow
26.66%
Financial Health
Equity Ratio
39.55%
Return on Equity
36.96%
ROCE
24.05%
ROIC
19.76%
Debt/Equity
0.72
More
EPS
$6.88
FCF per Share
$6.77
Short interest
1.59%
Employees
74.00k
Rev per Employee
$870.00k
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Merck & Co. forecast:

20x Buy
63%
12x Hold
38%

Analyst Opinions

32 Analysts have issued a Merck & Co. forecast:

Buy
63%
Hold
38%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
63,922 63,922
4% 4%
100%
- Direct Costs 13,956 13,956
10% 10%
22%
49,966 49,966
9% 9%
78%
- Selling and Administrative Expenses 10,779 10,779
4% 4%
17%
- Research and Development Expense 17,557 17,557
34% 34%
27%
26,244 26,244
0% 0%
41%
- Depreciation and Amortization 4,614 4,614
19% 19%
7%
EBIT (Operating Income) EBIT 21,630 21,630
4% 4%
34%
Net Profit 17,434 17,434
656% 656%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Positive
Seeking Alpha
one day ago
Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.
Positive
Seeking Alpha
3 days ago
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting th...
Positive
Forbes
4 days ago
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 74,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today